Showing 1891-1900 of 5771 results for "".
- Johnson & Johnson Vision Announces FDA Approval Of Tecnis Synergy And Tecnis Synergy Toric II IOLs In the UShttps://modernod.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/Johnson & Johnson Vision announced the FDA approval of Tecnis Synergy and Tecnis Synergy Toric II IOLs, and the Health Canada approval of Tecnis Synergy Toric II IOLs. This next-generation PCIOL is built on the legacy Tecnis platform and delivers a wide range of continuous vision with
- ProQR Therapeutics and Yarrow Biotechnology Announce Exclusive License and Discovery Collaboration for Undisclosed Ophthalmic Targethttps://modernod.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/RTW Investments and ProQR Therapeutics announced that Yarrow Biotechnology, a company newly created by RTW, has in-licensed exclusive rights to ProQR’s antisense oligonucleotide technology (ASO) to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Yarrow is f
- Oculis Announces Financing to Advance Topical Therapies for Posterior and Anterior Segmentshttps://modernod.com/news/oculis-announces-financing-to-advance-therapies-for-anterior-segment/2479162/Oculis announced that it has closed an oversubscribed $57 million Series C financing. Proceeds from this financing will accelerate Oculis’ strategy with the aim of delivering key goals in the near-term to drive shareholder value and bring transformative therapies to patients. The
- Clearside Biomedical Announces Resubmission of NDA for Xipere for Treatment of Macular Edema Associated with Uveitishttps://modernod.com/news/clearside-biomedical-announces-resubmission-of-nda-for-xipere-for-treatment-of-macular-edema-associated-with-uveitis/2479154/Clearside Biomedical announced the resubmission of its new drug application (NDA) to the FDA for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) for the treatment of macular edema associated with uveitis. Clearside’s resubmission is a f
- Samsung Bioepis Announces Analytical Similarity Data on SB11 (Ranibizumab) at ARVOhttps://modernod.com/news/samsung-bioepis-announces-analytical-similarity-data-on-sb11-ranibizumab-at-arvo/2479155/Samsung Bioepis announced results from a study analyzing structural and functional similarity between SB11, a proposed ranibizumab biosimilar, and Lucentis (ranibizumab). The study results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2021
- Oxurion NV Presenting Scientific Data at ARVO 2021 Annual Meetinghttps://modernod.com/news/oxurion-nv-presenting-scientific-data-at-arvo-2021-annual-meeting/2479144/Oxurion NV is announcing the presentation of novel scientific data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting which is held on May 1-7, 2021. The details of the presentation are as follows: Title: The Mouse Sodium Iodate Mo
- Nova Eye Medical Announces First Patient Enrolled in MAGIC Multicenter Canaloplasty Trial for Glaucomahttps://modernod.com/news/nova-eye-medical-announces-first-patient-enrolled-in-magic-multicenter-canaloplasty-trial-for-glaucoma/2479145/Nova Eye Medical Limited announced the enrollment of the first glaucoma patient in the multicenter ab-interno glaucoma study investigating canaloplasty (MAGIC) trial. The first MAGIC patie
- Okogen Announces Interim Analysis Results From RUBY Phase 2 Trial for Acute Adenoviral Conjunctivitis Drug Candidatehttps://modernod.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/Okogen announced the interim analysis results from RUBY, the company’s phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301
- Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302 Anti-VEGF for Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-the-phase-2-clinical-trial-of-ibi302-anti-vegf-for-wet-amd/2479137/Innovent Biologics announces that the first patient has been successfully dosed in a phase 2 clinical trial for IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein. This study is a randomized, double-blind, multicenter, active-cont
- Stealth BioTherapeutics Announces Poster Presentation at ARVOhttps://modernod.com/news/stealth-biotherapeutics-announces-poster-presentation-at-arvo/2479132/Stealth BioTherapeutics announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting, which is being held May 1-7, 2021. The poster showcases